(0.22%) 5 102.75 points
(0.56%) 38 597 points
(0.48%) 17 735 points
(0.33%) $79.21
(-0.39%) $2.03
(-0.08%) $2 307.70
(-0.20%) $26.78
(0.27%) $965.20
(0.02%) $0.932
(-0.07%) $10.98
(-0.06%) $0.797
(0.99%) $92.03
0.00% $ 8.50
Live Chart Being Loaded With Signals
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications...
Stats | |
---|---|
Volumen de hoy | 201 543 |
Volumen promedio | 659 643 |
Capitalización de mercado | 183.47M |
EPS | $0 ( 2024-02-13 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.12 |
ATR14 | $0.0160 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Syntone Ventures Llc | Buy | 714 286 | Common Stock |
2024-04-15 | Syntone Ventures Llc | Buy | 1 071 429 | Warrant (Right to Buy) |
2024-03-28 | Haddadin Yezan Munther | Buy | 1 882 | Common Stock |
2024-03-20 | Trenary C Russell Iii | Buy | 455 000 | Stock Option (Right to Buy) |
2024-03-20 | Evanson Jeff | Buy | 25 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
91.91 |
Last 99 transactions |
Buy: 132 469 020 | Sell: 31 433 684 |
Volumen Correlación
Outlook Therapeutics Inc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Outlook Therapeutics Inc Correlación - Moneda/Commodity
Outlook Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-44 188.00 (0.00 %) |
EPS: | $-4.72 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-44 188.00 (0.00 %) |
EPS: | $-4.72 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-204 694 (0.00 %) |
EPS: | $-6.23 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.350 |
Financial Reports:
No articles found.
Outlook Therapeutics Inc
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico